GALECTIN THERAPEUTICS INC
About GALECTIN THERAPEUTICS INC
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$30.8M
- Total assets
- $19.5M
- Market cap
- $153.4M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $20.1M
- Operating income
- -$20.1M
- Income tax
- $0
- Net income
- -$30.8M
- EPS (basic)
- $-0.48
- EPS (diluted)
- $-0.48
Balance sheet
- Total assets
- $19.5M
- Current assets
- $19.4M
- Total liabilities
- $145.7M
- Current liabilities
- $8.0M
- Shareholders’ equity
- -$127.9M
Cash flow
- Operating cash flow
- -$23.9M
- Investing cash flow
- -$2.6M
- Financing cash flow
- $26.5M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $153.4M
- EPS (diluted)
- $-0.48
- Shares outstanding
- 63.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 4, 2002
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $30.8M.
- Trading 63% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review GALECTIN THERAPEUTICS INC.
Write a review
News about GALECTIN THERAPEUTICS INC
News & sentiment via Polygon.io
